Monthly Roundup: Top 7 Primary Care Stories

In a real-world study of patients with Crohn disease, upadacitinib achieved 52.1% clinical remission at 12 weeks and 42.7% endoscopic remission at 6 months, with no new safety concerns reported.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

The increased risk of depression when oral contraceptives were started following childbirth was "instantaneous," researchers wrote, and was ~50% greater than nonuse.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Your daily dose of the clinical news you may have missed.

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.